Transcatheter Mitral & Tricuspid Therapies (TMTTs) are the future of Edwards – Estimated to be a more than $5 billion opportunity by 2028, Edwards will discuss its multiple transcatheter programs aimed at transforming care for the many patients suffering from mitral and tricuspid regurgitation. Since 2017 Edwards launched already 5 products – transformational therapies in Europe led by its CARDIOBAND, PASCAL and EVOQUE programs. Do you know we launched already second generation of Pascal – Pascal PRECISION is here and furthermore we are offering also Pascal ACE (very thin Pascal). Every patient is different - be an expert on our PASCAL device / therapy and help many patients suffering with regurgitation!
The Field Clinical Specialist PASCAL is responsible for education physician on Pascal technologies, device handling, implantation and troubleshooting techniques and case support by assigned hospitals / in assigned territories / regions.

Please refer the Job description for details